Showing results (221-230 of 336) with videos related to
Sort By:
Pageof 34
Journal of Human Genetics|November 3, 2009
hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological typeToshiki Okasaka, Keitaro Matsuo, Takeshi Suzuki, et al.JTO Clinical and Research Reports|April 9, 2026
Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With <i>EGFR</i> Mutation (West Japan Oncology Group 11719L: ADJUST Study)Ryota Shibaki, Hiroaki Akamatsu, Morihito Okada, et al.Cancer Science|July 3, 2019
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysisTomonori Hirashima, Miyako Satouchi, Toyoaki Hida, et al.Molecular Cancer Therapeutics|December 4, 2016
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung CancerYoshihisa Kobayashi, Koichi Azuma, Hiroki Nagai, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2017
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung CancerSuzanne Jenkins, James C-H Yang, Suresh S Ramalingam, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2009
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohortMarileila Varella-Garcia, Tetsuya Mitsudomi, Yashushi Yatabe, et al.Cancer Research and Treatment|July 27, 2019
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II StudiesMyung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2015
EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIsYoshihisa Kobayashi, Yosuke Togashi, Yasushi Yatabe, et al.Carcinogenesis|March 27, 2004
Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer riskHidemi Ito, Keitaro Matsuo, Nobuyuki Hamajima, et al.Molecular Cancer Therapeutics|July 31, 2012
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancerTakayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, et al.Pageof 34